Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Meibomian Gland Dysfunction Market Revenue Outlook: What CAGR Is Expected Through 2030?
The meibomian gland dysfunction market has experienced substantial expansion in recent years. It is forecast to expand from $4.42 billion in 2025 to $4.73 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. Factors contributing to its historical growth include the escalating incidence of dry eye disease, heightened screen time exposure, an expanding aging population, more extensive clinical recognition of mgd, and the presence of fundamental treatment options.
The meibomian gland dysfunction market is projected to experience substantial growth in the coming years, with its size reaching $6.12 billion by 2030, at a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is propelled by factors such as the increasing embrace of device-assisted therapies, escalating investments in ophthalmic care, heightened awareness of chronic eye conditions, the broadening availability of home-use treatment devices, and a stronger emphasis on personalized eye care. Key developments anticipated in this period encompass the wider acceptance of advanced diagnostic tools, an increase in the utilization of device-based therapies, a rising inclination towards combined treatment approaches, the growth of home-based management options, and a greater focus on detecting diseases early.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24602&type=smp
Meibomian Gland Dysfunction Market Expansion Drivers: What Is Shaping Future Growth?
An increase in eye disease instances is projected to boost the meibomian gland dysfunction (MGD) market going forward. An eye disease is defined as any ailment or condition impacting the eye or visual system, detrimentally affecting its structure, function, or general well-being. The surge in eye disease cases stems from extended screen time and digital eye strain, manifesting in symptoms like dryness, blurred vision, and potential long-term retinal damage from sustained blue light exposure. Meibomian gland dysfunction exacerbates eye disease by destabilizing the tear film, leading to inflammation, ocular dryness, and an elevated susceptibility to surface eye conditions. As an illustration, the National Institutes of Health (NIH), a US government agency, indicated in February 2025 that the worldwide prevalence of myopia is predicted to reach 36.59% by 2040 and 39.80% by 2050, with over 740 million total cases projected by 2050. Consequently, the increasing incidence of eye disease is propelling the expansion of the meibomian gland dysfunction (MGD) market.
Meibomian Gland Dysfunction Market Segmentation And Category Breakdown
The meibomian gland dysfunction market covered in this report is segmented –
1) By Treatment Type: Medication, Surgery, Lifestyle Modifications
2) By Dysfunction Type: Obstructive Meibomian Gland Dysfunction, Evaporative Meibomian Gland Dysfunction, Mixed Meibomian Gland Dysfunction
3) By Disease Severity: Mild Meibomian Gland Dysfunction, Moderate Meibomian Gland Dysfunction, Severe Meibomian Gland Dysfunction
4) By Distribution channel: Hospitals And Clinics, Pharmacies, Online Retailers
5) By End-User: Hospitals, Ophthalmology Clinics, Home Care Settings
Subsegments:
1) By Medication: Topical Antibiotics, Topical Steroids, Lubricating Eye Drops, Topical Cyclosporine, Omega-3 Supplements
2) By Surgery: Meibomian Gland Probing, Intense Pulsed Light (IPL) Therapy, Thermal Pulsation Treatment, BlephEx
3) By Lifestyle Modifications: Warm Compress Therapy, Lid Hygiene, Dietary Adjustments, Blinking Exercises
Meibomian Gland Dysfunction Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Leading companies in the meibomian gland dysfunction market are concentrating on developing novel therapies, such as prescription eye drop solutions, to minimize tear evaporation and alleviate dry eye symptoms. These prescription eye drop solutions, including anti-inflammatory or antibiotic varieties, assist in managing meibomian gland dysfunction by reducing inflammation, clearing gland blockages, and improving the stability of the tear film. For example, in May 2023, Bausch + Lomb Corporation, a Canada-based eye health company, unveiled MIEBO (perfluorohexyloctane ophthalmic solution), an innovative prescription eye drop specifically designed for treating dry eye disease (DED). As the first and only prescription eye drop to directly target tear evaporation, which is the primary cause of DED, MIEBO establishes a protective, enduring layer over the eye’s surface. Its distinctive water-free formulation delivers effective and prolonged relief, particularly for patients experiencing dry eye symptoms connected to Meibomian gland dysfunction.
Meibomian Gland Dysfunction Market Competitive Analysis Of Major Industry Participants
Major companies operating in the meibomian gland dysfunction market are Johnson And Johnson, Alcon Inc., Bausch Lomb Corporation, Santen Pharmaceutical, Lumenis Ltd, Topcon Healthcare Solutions Inc, AFT Pharmaceuticals, Sight Sciences Inc, OASIS Medical Inc, OCuSOFT Inc, Novaliq GmbH, Scope Ophthalmics Ltd, Medmont International Pty Ltd, Azura Ophthalmics Ltd, BlephEx LLC, Bruder Healthcare Company, ESW Vision Inc, MiBo Medical Group Inc, Kala Pharmaceuticals Inc, Allergan Eye Care, TearScience Inc, Sun Pharmaceutical Industries Ltd
Access The Complete Meibomian Gland Dysfunction Market Report:
https://www.thebusinessresearchcompany.com/report/meibomian-gland-dysfunction-global-market-report
Meibomian Gland Dysfunction Market Regional Analysis: Which Region Leads By Revenue?
North Americawas the largest region in the meibomian gland dysfunction market in 2025. The regions covered in the meibomian gland dysfunction market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
